Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
| Index | Nasdaq Biotechnology |
| Investeringsfocus | Equity, United States, Health Care |
| Fondsgrootte | EUR 753 m |
| Totale kostenratio (TER) | 0.35% p.a. |
| Replicatie | Fysiek (Geoptimaliseerde sampling) |
| Juridische structuur | ETF |
| Strategierisico | Langdurig |
| Duurzaamheid | No |
| Valuta van het fonds | USD |
| Valutarisico | Valuta niet gedekt |
| Volatiliteit 1 jaar (in EUR) | 21.34% |
| Startdatum/Noteringsdatum | 19 October 2017 |
| Distributiebeleid | Accumulerend |
| Distributiefrequentie | - |
| Vestigingsplaats van het fonds | Ireland |
| Fondsaanbieder | iShares |
| Fondsstructuur | Open-ended Investment Company (OEIC) |
| UCITS-conformiteit | Yes |
| Administrateur | State Street Fund Services (Ireland) Limited |
| Beleggingsadviseur | |
| Bewaarbank | State Street Custodial Services (Ireland) Limited |
| Revisiebedrijf | Deloitte |
| Einde belastingjaar | 31 May |
| Vertegenwoordiger van Zwitserland | BlackRock Asset Management Schweiz AG |
| Zwitserse uitbetalende instantie | State Street Bank International GmbH, Munich, Zurich Branch |
| Duitsland | 30% tax rebate |
| Zwitserland | ESTV Reporting |
| Oostenrijk | Tax Reporting Fund |
| UK | UK Reporting |
| Indextype | Totale rendementsindex |
| Swap tegenpartij | - |
| Collateral manager | Bank of New York Mellon|Euroclear|JP Morgan|State Street Bank |
| Effectenlening | Yes |
| Tegenpartij die effecten uitleent | Barclays Bank Plc|Barclays Capital Securities Ltd.|BNP Paribas Arbitrage SNC|BNP Paribas SA|Citigroup Global Markets Ltd|Citigroup Inc|Credit Suisse Securities (Europe) Ltd.|Deutsche Bank AG|Goldman Sachs International|HSBC Bank Plc|J.P. Morgan Securities Plc|JP Morgan Chase & Co|Macquarie Bank Limited|Merrill Lynch International|Morgan Stanley & Co. International Plc|Nomura International Plc|Skandinaviska Enskilda Banken AB|Societe Generale SA|The Bank of Nova Scotia|UBS AG |
| Gilead Sciences, Inc. | 9.34% |
| Vertex Pharmaceuticals | 9.05% |
| Amgen, Inc. | 8.97% |
| Regeneron Pharmaceuticals, Inc. | 5.98% |
| Alnylam Pharmaceuticals | 3.29% |
| Insmed | 2.40% |
| Biogen, Inc. | 2.07% |
| argenx | 1.69% |
| United Therapeutics | 1.63% |
| Moderna, Inc. | 1.52% |
| United States | 80.86% |
| Bermuda | 1.49% |
| Ireland | 1.36% |
| Other | 16.29% |
| Health Care | 86.31% |
| Consumer Staples | 0.02% |
| Other | 13.67% |
| YTD | +3,96% |
| 1 maand | +1,24% |
| 3 maanden | +1,94% |
| 6 maanden | +15,02% |
| 1 jaar | +46,71% |
| 3 jaar | +31,96% |
| 5 jaar | +30,55% |
| Since inception | +74,17% |
| 2025 | +17,44% |
| 2024 | +5,43% |
| 2023 | +0,53% |
| 2022 | -5,02% |
| Volatiliteit 1 jaar | 21,34% |
| Volatiliteit 3 jaar | 20,04% |
| Volatiliteit 5 jaar | 22,35% |
| Rendement/Risico 1 jaar | 2,19 |
| Rendement/Risico 3 jaar | 0,48 |
| Rendement/Risico 5 jaar | 0,24 |
| Maximaal waardedaling 1 jaar | -7,68% |
| Maximaal waardedaling 3 jaar | -25,56% |
| Maximaal waardedaling 5 jaar | -30,93% |
| Maximaal waardedaling sinds aanvang | -30,93% |
| Beursnotering | Handelsvaluta | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | 2B70 | - - | - - | - |
| Stuttgart Stock Exchange | EUR | 2B70 | - - | - - | - |
| Bolsa Mexicana de Valores | MXN | - | BTEC1N MM | BTEC1N.MX | |
| London Stock Exchange | USD | BTEC | BTEC LN INAVBTEU | BTEC.L 0WXSINAV.DE | |
| London Stock Exchange | GBP | BTEK | BTEK LN INAVBTEU | BTEK.L 0WXSINAV.DE | |
| SIX Swiss Exchange | USD | BTEC | BTEC SE INAVBTEU | BTEC.S 0WXSINAV.DE | |
| Xetra | EUR | 2B70 | 2B70 GY INAVBTEE | BTEC.DE 0WXNINAV.DE |
| Naam fonds | Fondsgrootte in €m (AuM) | TER p.j. | Distributie | Replicatiemethode |
|---|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 48 | 0,35% p.a. | Distribueren | Sampling |